An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease

Advanced Drug Delivery Reviews

Volumn 33, Issue 3, 1998, Pages 253-263

  Danhof, M ^a   Van Der Geest, R ^a   Van Laar, T ^b   Bodde H E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Controlled drug delivery; Parkinson's disease; Pharmacodynamics; Pharmacokinetic pharmacodynamic correlation; Pharmacokinetics; R apomorphine; Transdermal iontophoresis

Indexed keywords

AMINES; CORRELATION METHODS; DISEASES; DRUG INFUSION; PHARMACOKINETICS;

APOMORPHINE; TRANSDERMAL IONTOPHORESIS;

CONTROLLED DRUG DELIVERY;

APOMORPHINE;

CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; DRUG BLOOD LEVEL; DYSKINESIA; ENANTIOMER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IONTOPHORESIS; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SHORT SURVEY; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032494142     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00033-7     Document Type: Review

References (34)

1. A.J. Lees, Apomorphine and Parkinson's disease, in: J.P.W.F. Lakke, E.M. Delhaas, A.W.F. Rutgers (Eds.), Parenteral Drug Therapy in Spasticity and Parkinson's Disease, The Parthenon Publishing Group, Carnforth, 1992, pp. 185-192.
2. J.L. Neumeyer, S. Law, R.J. Baldessarini, Historical highlights of the chemistry, pharmacology and early clinical uses of apomorphine, in: G.L. Gessa, G.U. Corsini (Eds.), Apomorphine and other Dopamimetics, Raven Press, New York, 1981, pp. 1-17.
3. R.J. Baldessarmni, G.W. Arana, N.S. Kula, A. Campbell, M. Harding, Preclinical studies of the pharmacology of aporphines, in: G.L. Gessa, G.U. Corsini (Eds.), Apomorphine and other Dopamimetics, Raven Press, New York, 1981, pp. 219-228.
4. Cotzias G.C., Papavasiliou P.S., Tolosa E.S., Mendez J.S., Bell-Midura M. Treatment of Parkinson's disease with apomorphines. N. Engl. J. Med. 294:1976;567-572.
5. Gancher S.T., Nutt J.G., Woodward W.R. Absorption of apomorphine by various routes in parkinsonism. Mov. Disord. 6:1991;212-216.
6. Stibe C.M., Kempster P.A., Lees A.J., Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1:1988;403-406.
7. Van Laar T., Jansen E.N.H., Essink A.W.G., Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch. Neurol. 49:1992;482-484.
8. Montastruc J.L., Rascol O., Senard J.M. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. 14:1991;432-437.
9. Van Laar T., Jansen E.N.H., Essing A.W.G., Rutten W.J., Neef C. Rectal apomorphine: a new treatment modality in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 55:1992;737-738.
10. Breimer D.D. Pharmacokinetic and pharmacodynamic basis for peptide drug delivery system design. J. Control. Release. 21:1992;5-10.
11. Breimer D.D. An integrated pharmacokinetic and pharmacodynamic approach to controlled drug delivery. J. Drug. Target. 3:1996;411-415.
12. M. Danhof, J.W. Mandema, Modeling of relationships between pharmacokinetics and pharmacodynamics, in: P.G. Welling, F.L.S. Tse (Eds.), Pharmacokinetics - Regulatory, Industrial, Academic Perspectives, Marcel Dekker, New York, 1995, pp. 139-174.
13. Breimer D.D., Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'Wooden Shoe' paradigm. Clin. Pharmacokinet. 32:1997;259-267.
14. Holford N.H.G., Sheiner L.B. Understanding the dose-effect relationship: clinical applications of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6:1981;429-453.
15. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:1993;457-478.
16. Jusko W.J., Ko H.C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:1994;406-419.
17. D.D. Breimer, The need for rate and time programming in future drug delivery. Pharmacokinetic, pharmacodynamic and clinical considerations, in: R. Gurny, H.E. Junginger, N.A. Peppas (Eds.), Pulsatile Drug Delivery - Current Applications and Future Trends, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993, pp. 25-37.
18. L.Z. Benet, Input factors as determinants of drug activity: route, dose, dosage regimen and the drug delivery system, in: F.G. McMahon (Ed.), Principles and Techniques of Human Research and Therapeutics, Futura, New York, 1974, pp. 9-23.
19. M. Danhof, Parenteral neuropharmacological kinetics: pharmacokinetic aspects of controlled drug delivery to the brain, in: J.P.W.F. Lakke, E.M. Delhaas, A.W.F. Rutgers (Eds.), Parenteral Drug Therapy in Spasticity and Parkinson's Disease, The Parthenon Publishing Group, Carnforth, 1992, pp. 163-176.
20. J.E. Shaw, S.K. Chandrasekaran, Transdermal therapeutic systems, in: L.F. Prescott, W.S. Nimmo (Eds.), Drug Absorption, ADIS Press, Sydney, 1979, pp. 186-193.
21. W.S. Nimmo, Recent clinical experience with transdermal systems, in: L.F. Prescott, W.S. Nimmo (Eds.), Novel Drug Delivery, Churchill Livingstone, Edinburgh, 1989, pp. 209-221.
22. B.H. Sage, Iontophoresis, in: E.W. Smith, H.I. Maibach (Eds.), Percutaneous Penetration Enhancers, CRC Press, Boca Raton, 1995, pp. 351-368.
23. Yoshida N.H., Roberts M.S. Structure-transport relationships in transdermal iontophoresis. Adv. Drug. Del. Rev. 9:1992;239-264.
24. M. Danhof, J.W. Mandema, A.M. Stijnen, Pharmacokinetic complexities of in vivo pharmacodynamic investigations, in: C.J. Van Boxtel, N.H.G. Holford, M. Danhof (Eds.), The In Vivo Study of Drug Action - Concepts and Applications of Kinetic-Dynamic Modelling, Elsevier, Amsterdam, 1992, pp. 31-60.
25. 2 dopamine receptors. Mol. Pharmacol. 25:1984;18-23.
26. Cannon J.G., Smith R.V., Modiri A., Sood S.P., Borgman R.J., Aleem M.A., Long J.P. Centrally acting emetics: preparation and pharmacology of 10 hydroxy-11-methoxy-apomorphine (isoapocodeine). In vitro enzymatic methylation of apomorphine. J. Med. Chem. 15:1972;273-276.
27. Kaul P.N., Brochmann-Hansen E., Way E.L. Biological disposition of apomorphine. Urinary excretion and organ distribution of apomorphine. J. Pharm. Sci. 50:1961;244-247.
28. Van der Geest R., Krüger P.P., Gubbens-Stibbe J.M., Van Laar T., Boddé H.E., Danhof M. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. J. Chromatogr. Biomed. Appl. 702:1997;131-141.
29. Van der Geest R., Van Laar T., Gubbens-Stibbe J.M., Boddé H.E., Roos R.A.C., Danhof M. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. 21:1998;159-166.
30. Rehse K., Piesker G., Horowski R. Neuropsychotrope Aktivität und Toxicität von Oxidationsprodukten des Apomorphins. Arch. Pharmacol. 311:1977;360-363.
31. Van Laar T., Van der Geest R., Danhof M., Boddé H.E., Gossens P.H., Roos R.A.C. Stepwise intravenous infusion of R-apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin. Neuropharmacol. 21:1998;152-158.
32. Van der Geest R., Danhof M., Boddé H.E. Validation and testing of a new iontophoretic continuous flow through transport cell. J. Control. Release. 51:1998;85-91.
33. Van der Geest R., Danhof M., Boddé H.E. Iontophoretic delivery of apomorphine I. In vitro optimization and validation. Pharm. Res. 14:1997;1797-1802.
34. Van der Geest R., Van Laar T., Gubbens-Stibbe J.M., Boddé H.E., Danhof M. Iontophoretic delivery of R-apomorphine II: an in vivo study in patients with Parkinson's disease. Pharm. Res. 14:1997;1803-1809.